HTP Graphics

Aromatose Inhibitor SCENARIOS Aromatose Inhibitor As you may have gathered by now, Prof. Table is a busy man who is involved in a number of differing projects. Along with the new radiotherapy treatment he is developing with Prof. Kent, his other main venture is the development of the novel and highly effective Aromatose Inhibitor, for the treatment of breast cancer. He has undertaken this development with the capable assistance provided by Dr. Brian Hodgson, a Lecturer in Clinical Oncology at Lakeland. Prof. Table has undertaken much of his work in relation to the testing whilst on secondment at IPP. Brian, however, is solely based at Lakeland. IPP is extremely interested in the possibilities for the new radiotherapy treatment to be a new drug therapy for breast cancer, as early tests have given excellent results. IPP is keen to ensure protection of the invention from an early stage. Its marketing team has even come up with the name AROINHIB to market the drug under. IPP is currently considering whether it can and should protect the name as a trade mark in the UK, the European Community and any other countries in which the Aromatose Inhibitor could be marketed. This time, imagine that you are taking Prof. Table's and Brian Hodgson's roles. In the case of Prof. Table, you have to wear a number of different hats – he works at Lakeland, yet his Chair is funded by IPP and he is actually seconded there as well. Have a think about the potential conflicts of interest and issues that these diverse roles might create. Brian's seems to be a much more straightforward role as he does not have any interests other than his academic and research career at Lakeland. Think also about how IPP's involvement might affect the issues. It seems keen to protect Prof. Table's and Brian Hodgson's work, but is it possible for it to do that bearing in mind that both the inventors are employees of Lakeland? Does IPP have rights in the work being undertaken by Prof. Table and Brian Hodgson? 14

• Cover